As of 2024-12-14, the EV/EBITDA ratio of Prostatype Genomics AB (PROGEN.ST) is -1.50. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PROGEN.ST's latest enterprise value is 54.35 mil SEK. PROGEN.ST's TTM EBITDA according to its financial statements is -36.23 mil SEK. Dividing these 2 quantities gives us the above PROGEN.ST EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 17.4x - 24.9x | 20.0x |
| Forward P/E multiples | 17.8x - 24.4x | 19.2x |
| Fair Price | (124.60) - (171.60) | (137.55) |
| Upside | -1243.2% - -1674.3% | -1361.9% |
| Date | EV/EBITDA |
| 2024-12-13 | -1.50 |
| 2024-12-12 | -1.56 |
| 2024-12-11 | -1.49 |
| 2024-12-10 | -1.66 |
| 2024-12-09 | -1.57 |
| 2024-12-06 | -1.14 |
| 2024-12-05 | -1.11 |
| 2024-12-04 | -1.12 |
| 2024-12-03 | -1.22 |
| 2024-12-02 | -1.09 |
| 2024-11-29 | -1.02 |
| 2024-11-28 | -1.04 |
| 2024-11-27 | -0.91 |
| 2024-11-26 | -0.97 |
| 2024-11-25 | -0.99 |
| 2024-11-22 | -1.12 |
| 2024-11-21 | -1.06 |
| 2024-11-20 | -1.08 |
| 2024-11-19 | -1.07 |
| 2024-11-18 | -1.12 |
| 2024-11-15 | -1.16 |
| 2024-11-14 | -1.16 |
| 2024-11-13 | -1.27 |
| 2024-11-12 | -1.33 |
| 2024-11-11 | -1.34 |
| 2024-11-08 | -1.46 |
| 2024-11-07 | -1.41 |
| 2024-11-06 | -1.47 |
| 2024-11-05 | -1.50 |
| 2024-11-04 | -1.61 |
| 2024-11-01 | -1.51 |
| 2024-10-31 | -1.59 |
| 2024-10-30 | -1.66 |
| 2024-10-29 | -1.80 |
| 2024-10-28 | -1.80 |
| 2024-10-25 | -1.80 |
| 2024-10-24 | -1.87 |
| 2024-10-23 | -1.73 |
| 2024-10-22 | -1.87 |
| 2024-10-21 | -1.87 |
| 2024-10-18 | -1.87 |
| 2024-10-17 | -1.87 |
| 2024-10-16 | -1.94 |
| 2024-10-15 | -2.01 |
| 2024-10-14 | -2.08 |
| 2024-10-11 | -1.87 |
| 2024-10-10 | -1.87 |
| 2024-10-09 | -1.80 |
| 2024-10-08 | -1.87 |
| 2024-10-07 | -1.87 |